Author: kodiac

  • Alpha-GPC

    Plain-language summaryIntrigue 64 / 100

    Alpha-GPC is a phospholipid that delivers choline to the brain efficiently. It supports acetylcholine production and is one of the more bioavailable choline supplements. Used in nootropic stacks alongside racetams to prevent the headaches some users experience from racetam-induced choline depletion. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Phospholipid-derived cholinergic precursor and acetylcholine biosynthetic substrate

    A high-bioavailability choline donor derived from phosphatidylcholine hydrolysis, developed in Italy as a prescription cholinergic agent for cognitive impairment and cerebrovascular disease, distinguished from other choline sources by efficient blood-brain barrier penetration and dual contribution of choline for acetylcholine synthesis and glycerophosphate for membrane phospholipid remodeling.

    Abstract

    Alpha-GPC (L-alpha-glycerylphosphorylcholine; choline alfoscerate; sn-glycero-3-phosphocholine; CAS 28319-77-9; molecular formula C8H20NO6P; molecular weight 257.22 g/mol) is an endogenous phospholipid intermediate in the deacylation pathway of membrane phosphatidylcholine and an exogenous cholinergic precursor that delivers bioavailable choline across the blood-brain barrier more efficiently than choline salts, choline bitartrate, or lecithin. The compound contains approximately 40 percent choline by mass, is freely water-soluble, highly hygroscopic, and is metabolized by phosphodiesterases in the intestinal mucosa and in central and peripheral tissues to yield free choline and glycerol-3-phosphate. The released choline serves as the immediate biosynthetic substrate for choline acetyltransferase-catalyzed acetylcholine synthesis in cholinergic neurons, while the glycerophosphate moiety enters the Kennedy pathway for phosphatidylcholine resynthesis, providing simultaneous support for neurotransmitter production and neuronal membrane integrity.

    Alpha-GPC was first synthesized by Baer and Kates in 1948 and entered pharmaceutical development in Italy in the 1980s under the trade names Gliatilin and Delecit. It is registered as a prescription medicine in Italy, Russia, and several Eastern European and Asian jurisdictions for the treatment of cognitive impairment associated with Alzheimer disease, cerebrovascular disease, and post-stroke cognitive decline. In the United States it is classified as a dietary supplement and is not regulated as a drug. The compound has accumulated a substantial clinical evidence base across multiple indications: a 2044-patient Italian multicenter trial in acute cerebrovascular disease (Barbagallo Sangiorgi et al. 1994); the De Jesus Moreno (2003) 261-patient multicenter randomized double-blind placebo-controlled trial demonstrating significant improvement on the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Mini-Mental State Examination (MMSE), and Global Deterioration Scale (GDS) at 1200 mg/day for 180 days in mild-to-moderate Alzheimer dementia; multiple open-label and controlled studies of combination therapy with acetylcholinesterase inhibitors; and recent systematic reviews and meta-analyses (Sagaro et al. 2023) confirming efficacy in adult-onset cognitive dysfunction with pooled effect sizes favoring alpha-GPC over placebo and over citicoline in head-to-head comparisons. Additional research applications include augmentation of growth hormone secretion during resistance exercise (Ziegenfuss et al. 2008), enhancement of peak force production in trained athletes, and investigation of motivational and attentional endpoints in healthy volunteers.

    Pharmacokinetics are characterized by rapid oral absorption with peak plasma choline elevation at approximately 1 to 2 hours, a choline elevation half-life of 4 to 8 hours, oral bioavailability exceeding 40 percent for choline delivery, and metabolism through phosphodiesterase-mediated hydrolysis rather than cytochrome P450-dependent pathways. The compound distributes widely, with particular concentration in brain, liver, and kidney. Excretion is predominantly renal as polar choline metabolites and expired carbon dioxide from betaine oxidation.

    The safety profile at registered doses (400 to 1200 mg/day) is favorable; the most commonly reported adverse events are mild gastrointestinal disturbance (nausea, heartburn, diarrhea), headache, and insomnia, occurring at rates modestly above placebo. A 2021 Korean retrospective cohort study (Lee et al. 2021) raised a signal for increased stroke risk with long-term alpha-GPC use, a finding that requires replication and mechanistic investigation. The proposed mechanism involves conversion of choline to trimethylamine by gut microbiota, hepatic oxidation to trimethylamine N-oxide (TMAO), and TMAO-mediated promotion of atherosclerosis and thrombosis. This signal has not been confirmed in prospective controlled trials and does not apply to short-term or moderate-dose use.

    This monograph documents the chemistry, synthesis, and preparation of alpha-GPC; the cholinergic precursor mechanism and downstream pharmacology; comprehensive pharmacokinetics; the clinical evidence base across cognitive, cerebrovascular, sport-performance, and adjunctive indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and safety signal; and a structured comparative assessment of five alternative choline donors and cholinergic precursors (citicoline, choline bitartrate, phosphatidylcholine, DMAE, and centrophenoxine) against alpha-GPC on five standards: bioavailability, effect size, clinical validation, side-effect profile, and overall utility.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1443Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Centrophenoxine

    Plain-language summaryIntrigue 52 / 100

    Centrophenoxine (meclofenoxate) is a 1959-vintage cognitive enhancer that pairs DMAE, a choline-related compound, with a small chlorinated acid. After it crosses into the brain, it splits and does two things: it feeds the acetylcholine system and it helps clear lipofuscin, the brownish junk pigment that accumulates inside aged brain and skin cells. The lipofuscin clearance angle is the unusual part; few compounds do it. It has been sold as a memory drug in Europe and Latin America since the 1960s for senile cognitive impairment, but the modern clinical evidence is thin and mostly old. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Cholinergic precursor ester combining dimethylaminoethanol and 4-chlorophenoxyacetic acid with lipofuscin-clearing and neuroprotective activity

    A synthetic ester of dimethylaminoethanol and para-chlorophenoxyacetic acid developed in 1959 at the French National Scientific Research Center, distinguished from other cholinergic precursors by its capacity to reduce neuronal lipofuscin accumulation and to enhance phospholipid membrane turnover in aging brain tissue.

    Abstract

    Centrophenoxine (meclofenoxate, Lucidril; 2-(dimethylamino)ethyl (4-chlorophenoxy)acetate; CAS 51-68-3; molecular formula C12H16ClNO3; molecular weight 257.71 g/mol) is a synthetic cholinergic precursor and neuroprotective agent developed in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France. The compound is an ester of two biologically active moieties: dimethylaminoethanol (DMAE), a naturally occurring aminoalcohol found in small quantities in the human brain and implicated in choline and phospholipid metabolism, and para-chlorophenoxyacetic acid (pCPA), a synthetic auxin derivative that serves as a lipophilic carrier facilitating blood-brain barrier penetration and extending the biological half-life of the DMAE component. Following oral administration, centrophenoxine undergoes rapid hepatic ester hydrolysis to release DMAE and pCPA. The DMAE moiety is subsequently methylated to choline, which enters the acetylcholine synthetic pathway and is incorporated into membrane phospholipids as phosphatidyldimethylaminoethanol and phosphatidylcholine. The compound’s most distinctive pharmacological feature is the reduction of lipofuscin, the heterogeneous age pigment that accumulates progressively in postmitotic cells including cortical and hippocampal neurons, cardiac myocytes, and retinal pigment epithelium. The lipofuscin-clearing activity was first demonstrated by Nandy and Bourne in 1966 in senile guinea pig neurons and has been replicated across multiple rodent species, with reductions of 25 to 40 percent in cortical and hippocampal lipofuscin content following chronic oral administration at doses of 40 to 80 mg/kg/day for three to six months [1, 2]. The mechanism of lipofuscin clearance is incompletely characterized but is attributed to a combination of enhanced lysosomal enzyme activity, increased membrane phospholipid turnover (which dilutes the lipofuscin granule burden through membrane remodeling), and direct free radical scavenging by the DMAE moiety, which is incorporated into neuronal membranes as phosphatidyl-DMAE and functions as a hydroxyl radical scavenger [3, 4]. The clinical evidence base in human cognitive impairment spans approximately five decades but is modest in scale and quality by contemporary standards. The largest double-blind, randomized, placebo-controlled trial in healthy elderly subjects (Marcer and Hopkins, 1977; n = 50) demonstrated significant improvement in delayed free recall after three months of oral centrophenoxine at 600 mg twice daily, with no effect on immediate recall, digit span, or recognition memory, suggesting a selective enhancement of memory consolidation into long-term storage [5]. A second double-blind trial in 50 patients with organic dementia (Pek and Fulop, 1983) reported improvement in 48 percent of centrophenoxine-treated subjects versus 28 percent on placebo, although with high variability and methodological limitations [6]. Smaller open-label and controlled studies have reported improvements in vigilance, reaction time, and subjective mental alertness in elderly populations. The compound is marketed as a prescription medicine in several European countries (France, Germany, Hungary, Austria), in Japan, and in parts of Latin America for indications including senile cognitive impairment, post-stroke cognitive rehabilitation, and alcohol-related cognitive decline. It is not approved by the United States Food and Drug Administration and is sold as a research chemical in the United States. Pharmacokinetics are characterized by rapid oral absorption, rapid hepatic ester hydrolysis (plasma half-life of the parent ester is approximately 30 to 60 minutes), and a longer effective duration attributable to the persistence of the DMAE metabolite in brain tissue. Typical clinical doses range from 600 to 2000 mg per day in two or three divided administrations. The adverse-event profile is favorable; the most commonly reported effects are mild gastrointestinal discomfort, insomnia, and headache, generally at higher doses and resolving with dose reduction. This monograph reviews the chemistry, synthesis, and structural pharmacology of centrophenoxine; the lipofuscin-clearing, cholinergic, antioxidant, and membrane-modifying mechanisms; the pharmacokinetic profile; the preclinical and clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions with racetams and other cholinergic agents; the adverse-event and safety profile; and a comparative assessment of five cholinergic and neuroprotective alternatives (alpha-GPC, citicoline, DMAE, piracetam, and idebenone) against centrophenoxine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1445Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Solriamfetol

    Plain-language summaryIntrigue 68 / 100

    Solriamfetol, sold as Sunosi, is a wakefulness-promoting medication FDA-approved in 2019 for daytime sleepiness in narcolepsy and obstructive sleep apnea. It is a selective dopamine and norepinephrine reuptake inhibitor with clean pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Selective dopamine and norepinephrine reuptake inhibitor (DNRI) with trace amine-associated receptor 1 (TAAR1) agonist activity

    A phenylalanine-derived dual dopamine-norepinephrine reuptake inhibitor developed by SK Biopharmaceuticals and commercialized by Jazz Pharmaceuticals as the first DNRI approved for the treatment of excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea.

    Abstract

    Solriamfetol (JZP-110, SKL-N05, ADX-N05) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) approved in the United States (March 2019) and the European Union (January 2020) for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy or obstructive sleep apnea (OSA). Chemically derived from the amino acid D-phenylalanine, solriamfetol is the (R)-enantiomer of 2-amino-3-phenylpropyl carbamate and is supplied as the hydrochloride salt for oral administration. The compound inhibits the reuptake of dopamine (IC50 approximately 2.9 micromolar) and norepinephrine (IC50 approximately 4.4 micromolar) at their respective plasma membrane transporters (DAT and NET) with minimal activity at the serotonin transporter. In addition, solriamfetol acts as an agonist at the human trace amine-associated receptor 1 (TAAR1) with an EC50 of approximately 10 to 16 micromolar, a concentration range overlapping its DAT and NET inhibitory potencies and achieved at clinically relevant plasma levels. Critically, the compound does not promote monoamine release, distinguishing it mechanistically from amphetamine and its analogs and supporting its classification as a reuptake inhibitor rather than a releasing agent. The clinical development program comprised five pivotal trials (TONES 1 through TONES 5). The Phase 3 TONES 2 trial in 231 narcolepsy patients demonstrated that solriamfetol at 150 mg and 300 mg once daily produced statistically significant improvements in the Maintenance of Wakefulness Test (MWT) mean sleep latency (increases of 9.8 and 12.3 minutes, respectively, versus 2.1 minutes for placebo at 12 weeks) and in the Epworth Sleepiness Scale (ESS). The Phase 3 TONES 3 trial in 459 OSA patients demonstrated similar dose-dependent improvements at 37.5, 75, 150, and 300 mg doses. The long-term TONES 5 open-label extension in 643 participants confirmed maintenance of efficacy and tolerability over 52 weeks. A randomized withdrawal phase within TONES 5 demonstrated that participants switched to placebo experienced a return of sleepiness (ESS worsening of 5.3 points versus 1.6 points for those continuing solriamfetol), confirming sustained pharmacological activity rather than natural remission. Pharmacokinetics are notable for high oral bioavailability (approximately 95 percent), minimal hepatic metabolism (less than 1 percent of dose recovered as the sole inactive metabolite N-acetyl solriamfetol), and predominant renal elimination of unchanged drug through active tubular secretion. The elimination half-life is approximately 7.1 hours in subjects with normal renal function. Because metabolism is negligible, solriamfetol carries essentially no cytochrome P450 drug interaction liability. However, renal impairment substantially prolongs elimination (half-life increased approximately 1.2-, 1.9-, and 3.9-fold in mild, moderate, and severe renal impairment, respectively), requiring dose adjustment in moderate and severe renal impairment and avoidance in end-stage renal disease. The principal adverse events are headache, nausea, decreased appetite, insomnia, and anxiety. Solriamfetol produces small, dose-dependent increases in systolic blood pressure (0.5 to 2.5 mmHg), diastolic blood pressure, and heart rate (0.7 to 2.9 beats per minute), consistent with its noradrenergic mechanism. Concurrent use with monoamine oxidase inhibitors is contraindicated. The compound is designated Schedule IV in the United States, reflecting low but measurable abuse potential at supratherapeutic doses. This monograph reviews the chemistry, synthesis, and stereochemistry of solriamfetol; the dual-transporter and TAAR1 pharmacology; the comprehensive pharmacokinetic profile; the clinical evidence base across narcolepsy and OSA indications; the sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction implications; adverse-event signal; and a comparative assessment of five wake-promoting agents against solriamfetol on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1441Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pitolisant

    Plain-language summaryIntrigue 76 / 100

    Pitolisant, sold as Wakix, is a wakefulness-promoting medication that works through histamine receptors rather than dopamine. By blocking the H3 histamine autoreceptor (which normally puts a brake on histamine release), it increases brain histamine. FDA-approved for narcolepsy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Histamine H3 receptor inverse agonist/antagonist with secondary sigma-1 receptor agonism and wake-promoting eugeroic activity

    A first-in-class non-imidazole piperidine derivative developed at Bioprojet as a selective histamine H3 receptor inverse agonist, approved for narcolepsy-associated excessive daytime sleepiness and cataplexy, and distinguished from conventional stimulants by histaminergic wake promotion without dopaminergic reinforcement or controlled-substance classification.

    Abstract

    Pitolisant (BF2.649, Wakix) is the first histamine H3 receptor inverse agonist/antagonist to achieve regulatory approval, authorized by the European Medicines Agency in March 2016 and by the United States Food and Drug Administration in August 2019 for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The compound is a non-imidazole piperidine derivative, chemically designated 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine hydrochloride, that binds the human histamine H3 receptor with sub-nanomolar affinity (Ki approximately 0.3 to 1.0 nM) and functions as a potent inverse agonist at the constitutively active receptor with an EC50 of approximately 1.5 nM [1, 2]. By antagonizing presynaptic H3 autoreceptors on tuberomamillary histaminergic neurons, pitolisant enhances endogenous histamine synthesis and release, thereby activating downstream wake-promoting circuitry including noradrenergic, dopaminergic, and cholinergic projection systems, without direct dopaminergic reinforcement in the nucleus accumbens [3, 4]. This mechanistic distinction from amphetamine, modafinil, and solriamfetol is the pharmacological basis for the compound’s classification as a non-controlled substance in both the United States and the European Union, a clinically meaningful regulatory differentiation in a therapeutic area historically dominated by Schedule II and Schedule IV agents. The clinical evidence base for pitolisant in narcolepsy rests on the HARMONY trial program: HARMONY 1 demonstrated statistically significant reduction in Epworth Sleepiness Scale scores versus placebo (Cohen’s d 0.61) and significant reduction in weekly cataplexy rate (62% versus 8% for placebo) [5, 6]; HARMONY CTP confirmed anti-cataplectic efficacy with a Cohen’s d of 0.86 and a 75% reduction in weekly cataplexy rate versus 38% for placebo [7]; and HARMONY III established long-term safety and efficacy over 12 months of continuous dosing [8]. The FDA subsequently expanded the indication to include cataplexy in adults with narcolepsy (October 2020) and both excessive daytime sleepiness and cataplexy in pediatric patients aged 6 years and older (2024 and February 2026, respectively) [9]. Beyond narcolepsy, the HAROSA trial program has demonstrated efficacy for residual excessive daytime sleepiness in obstructive sleep apnea, with statistically significant ESS reductions at both 20 mg and 40 mg doses [10, 11]. Exploratory clinical and preclinical investigations extend to epilepsy, Prader-Willi syndrome, Parkinson’s disease-associated sleepiness, cognitive impairment, and obesity. Pharmacokinetics are characterized by high oral bioavailability (approximately 90%), rapid absorption with peak plasma concentrations at approximately 3 hours, plasma protein binding of 91 to 96%, and hepatic metabolism primarily via CYP2D6 and secondarily via CYP3A4, producing inactive metabolites conjugated with glycine or glucuronic acid [12]. The elimination half-life is 10 to 12 hours in most published pharmacokinetic analyses, though some reports note a range extending to 20 hours depending on the analytical methodology and population studied. CYP2D6 poor metabolizers exhibit approximately 2.4-fold increases in area under the curve, necessitating dose adjustment to a maximum of 17.8 mg daily in this population. The compound is well tolerated at approved doses of 8.9 to 35.6 mg daily; the principal adverse events are headache, insomnia, and nausea, with dose-dependent incidence [13]. QT interval prolongation is identified in the prescribing label, and the compound should be used with caution in patients with known QT prolongation or concurrent QT-prolonging medications. This monograph reviews the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical pharmacology, clinical evidence base across all studied indications, sourcing and quality verification, reconstitution and handling, stack interactions, adverse-event signal, and a comparative assessment of five alternative wake-promoting or histamine-modulating agents against pitolisant on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1442Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Piracetam

    Plain-language summaryIntrigue 65 / 100

    Piracetam is the original racetam, synthesized in 1964 and the prototype of the entire nootropic concept. It was developed at UCB Pharma and is approved in many countries for cognitive impairment. It is the lowest-potency racetam with minimal side effects, often used as a starting point for racetam research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    2-Oxopyrrolidine acetamide nootropic and positive allosteric modulator of AMPA-type glutamate receptors

    A cyclic GABA derivative synthesized at UCB Pharma as the prototype nootropic agent, distinguished by positive allosteric modulation of AMPA receptors, restoration of membrane fluidity under hypoxic and aging conditions, inhibition of platelet aggregation, and a six-decade clinical record spanning cortical myoclonus, age-related cognitive decline, and acute ischemic stroke.

    Abstract

    Piracetam (2-oxo-1-pyrrolidineacetamide), the founding member of the racetam class and the first compound for which the term “nootropic” was coined, is a cyclic derivative of gamma-aminobutyric acid (GABA) that lacks direct GABAergic receptor activity and instead exerts its principal pharmacological effects through positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptors, restoration of neuronal membrane fluidity, inhibition of voltage-gated N-type calcium channels, and rheological modification of erythrocyte and platelet function. Synthesized in 1964 by Corneliu Giurgea at the Belgian pharmaceutical company UCB under the development code UCB 6215, piracetam was initially investigated as a GABA-related sedative-hypnotic but was rapidly recognized to possess a pharmacological profile fundamentally distinct from GABA agonism: it enhanced learning and memory in animal models without producing sedation, anxiolysis, or anticonvulsant activity at therapeutic doses, and it exhibited an exceptionally favorable safety profile with no identified lethal dose in standard rodent toxicology. Giurgea formalized this novel pharmacological category in 1972 by coining the term “nootropic” from the Greek nous (mind) and trepein (to bend), establishing criteria that included enhancement of learning and memory, protection of the brain against physical or chemical injury, enhancement of cortical and subcortical control mechanisms, and absence of the pharmacological profile of typical psychotropic drugs. The molecular pharmacology of piracetam centers on a weak but functionally relevant positive allosteric modulation of AMPA receptors, characterized crystallographically by Ahmed and Oswald (2010) as binding at a novel site along the AMPA receptor dimer interface distinct from the aniracetam and cyclothiazide binding sites [1]. At concentrations achieved by standard oral dosing (approximately 100 micromolar in cerebrospinal fluid after a 1200 mg oral dose), piracetam enhances AMPA receptor-mediated calcium influx, reduces receptor desensitization, and facilitates glutamatergic neurotransmission in cortical and hippocampal circuits. A second major mechanism is the restoration of membrane fluidity in aged, hypoxic, or otherwise compromised neuronal membranes through direct interaction with the phospholipid bilayer headgroup region, improving the mobility and function of membrane-embedded receptors and ion channels [2]. A third mechanism, inhibition of voltage-gated N-type calcium channels at low micromolar concentrations (IC50 approximately 3 micromolar in rat cortical neurons), contributes to neuroprotective activity under ischemic conditions [3]. Pharmacokinetics are characterized by near-complete oral absorption (bioavailability approaching 100 percent), absence of hepatic metabolism (no metabolites have been identified in any species), renal excretion of the unchanged compound accounting for greater than 98 percent of the administered dose, and a plasma elimination half-life of approximately 5 hours in adults with normal renal function [4, 5]. The cerebrospinal fluid half-life is approximately 8 hours, consistent with the sustained central nervous system activity observed clinically. The pharmacokinetic profile is uncomplicated by cytochrome P450 interactions, protein binding effects, or hepatic disease sensitivity; the sole clinically relevant pharmacokinetic modifier is renal function, with dose adjustment required in renal impairment and the half-life extending to approximately 59 hours in anuric end-stage renal disease. The clinical evidence base spans six decades and multiple indications. The strongest evidence supports the use of piracetam in cortical myoclonus, where it is approved in the United Kingdom and several European jurisdictions at high doses (7.2 to 24 grams per day) as adjunctive therapy, with randomized controlled trial evidence demonstrating significant improvement in motor disability, functional capacity, and global assessment scores [6, 7]. A second major clinical application is age-related cognitive decline and dementia, where a 2002 meta-analysis of 19 double-blind placebo-controlled trials by Waegemans et al. reported a global effect favoring piracetam across a heterogeneous population of older patients with cognitive impairment [8], while a 2012 Cochrane systematic review by Flicker and Grimley Evans concluded that the evidence was suggestive but insufficient to support routine clinical use in dementia [9]. A more recent 2024 systematic review and meta-analysis by Fang et al. of 18 studies and 886 patients reported mixed findings, with some measures of cognitive function showing benefit but overall memory outcomes failing to reach clinical significance [10]. A third clinical application, acute ischemic stroke, was studied in the Piracetam in Acute Stroke Study (PASS), a multicenter randomized trial of 927 patients receiving 12 grams intravenously within 12 hours of stroke onset, which did not demonstrate significant benefit on the primary endpoint but showed a signal of efficacy in the subgroup treated within 7 hours [11, 12]. The compound is well tolerated. The principal safety considerations are dose-dependent inhibition of platelet aggregation with prolongation of bleeding time at high doses (a class effect that warrants caution in patients with hemorrhagic risk factors, concurrent anticoagulant therapy, or pre-surgical status), and the requirement for gradual dose tapering in myoclonus patients to avoid withdrawal-related seizure exacerbation [13]. Common adverse events are mild and include nervousness, hyperkinesia, somnolence, and weight gain, with no organ toxicity identified in chronic dosing studies extending to years of treatment. The compound is not approved by the United States Food and Drug Administration and is classified as a dietary supplement ingredient or research compound in the United States; it is a registered prescription medicine in over 60 jurisdictions worldwide. This monograph reviews the chemistry, synthesis, and structural class of piracetam; the molecular pharmacology at AMPA receptors, neuronal membranes, and calcium channels; the comprehensive pharmacokinetic record; the clinical evidence base across myoclonus, cognitive impairment, stroke, and additional indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events and safety signals; and a comparative assessment of five racetam-class alternatives against piracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1425Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Aniracetam

    Plain-language summaryIntrigue 62 / 100

    Aniracetam is a more potent racetam approved in Europe and Asia. It modulates AMPA glutamate receptors, slowing receptor desensitization, and is reported to have anxiolytic effects beyond cognition. Fat-soluble (best absorbed with food). Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Pyrrolidinone-class positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with secondary cholinergic, dopaminergic, and serotonergic neuromodulatory activity

    A lipophilic racetam nootropic developed at Hoffmann-La Roche as a cognition enhancer for cerebrovascular and neurodegenerative disorders, distinguished from piracetam by higher potency, oral lipophilicity, AMPA receptor positive allosteric modulation, and multi-target downstream activation of cholinergic, dopaminergic, and serotonergic neurotransmission through pharmacologically active metabolites.

    Abstract

    Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone; Ro 13-5057) is a lipophilic pyrrolidinone derivative of the racetam structural class, originally synthesized at Hoffmann-La Roche in the late 1970s as a more potent and centrally bioavailable analog of piracetam for the treatment of cognitive dysfunction associated with cerebrovascular disease and neurodegenerative dementia. The compound is classified as a positive allosteric modulator (PAM) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor, a mechanism that slows both channel deactivation and receptor desensitization at synaptic AMPA receptors, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic neurotransmission in cortical and hippocampal circuits critical for learning and memory [1, 2]. Beyond the direct AMPA receptor modulation, aniracetam and its principal active metabolite N-anisoyl-gamma-aminobutyric acid (N-anisoyl-GABA, which accounts for 70 to 80 percent of the metabolic disposition) exert downstream effects on multiple neurotransmitter systems: enhancement of acetylcholine release in the prefrontal cortex and hippocampus via group II metabotropic glutamate receptor modulation; site-specific activation of dopaminergic and serotonergic transmission in the mesocorticolimbic pathway through nicotinic acetylcholine receptor mechanisms; and anxiolytic activity mediated through an interaction between cholinergic, dopaminergic, and serotonergic systems [3, 4, 5]. The pharmacokinetic profile of aniracetam is characterized by rapid and complete gastrointestinal absorption, extremely low systemic bioavailability of the parent compound (approximately 0.2 percent) due to extensive first-pass hepatic hydrolysis, and a plasma elimination half-life of approximately 35 minutes [6, 7]. The parent compound is rapidly cleaved to yield three primary metabolites: N-anisoyl-GABA (70 to 80 percent), 2-pyrrolidinone (20 to 30 percent), and p-anisic acid (20 to 30 percent), each of which has been shown to contribute to the pharmacological activity profile [8]. The clinical evidence base for aniracetam derives principally from two double-blind, placebo-controlled multicenter trials in elderly patients with mild to moderate senile dementia of the Alzheimer type (SDAT), in which aniracetam at 1500 mg per day for six months produced statistically significant improvement in cognitive and psychobehavioral parameters relative to placebo and, in one trial, relative to piracetam at 2400 mg per day [9, 10]. A comparative open-label study in 276 patients with cognitive disorders demonstrated preservation of neuropsychological parameters for at least 12 months with aniracetam monotherapy and performance comparable to or exceeding cholinesterase inhibitor monotherapy in mildly demented patients [11]. Preclinical pharmacology is extensive and demonstrates cognitive enhancement in scopolamine-induced amnesia, cerebral ischemia, and age-related cognitive decline models; anxiolytic activity in elevated plus-maze, conditioned fear, and social interaction paradigms; neuroprotection against excitotoxicity and ischemic injury; and activation of brain-derived neurotrophic factor synthesis [12, 13, 14]. The compound was marketed as a prescription medicine in Japan (Draganon, subsequently withdrawn), in Italy (Ampamet), and in Greece (Memodrin, Referan) for cognitive impairment associated with cerebrovascular disease and neurodegenerative conditions. It is not approved by the United States Food and Drug Administration and is not a controlled substance in the United States, where it is sold as a research compound. This monograph reviews the chemistry, synthesis, and structural pharmacology of aniracetam; the multi-target mechanism of action spanning AMPA receptor modulation, metabotropic glutamate receptor effects, and monoaminergic neuromodulation; the comprehensive pharmacokinetic record including active metabolite characterization; the preclinical pharmacology across cognitive, anxiolytic, and neuroprotective domains; the clinical evidence base in dementia and cognitive impairment; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety; and a comparative assessment of five racetam and ampakine alternatives against aniracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1426Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pramiracetam

    Plain-language summaryIntrigue 55 / 100

    Pramiracetam is a more potent piracetam analog with strong effects on hippocampal acetylcholine release. It is used in Italy for neurological disorders and is popular in nootropic communities for memory enhancement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Diisopropylaminoethyl 2-oxopyrrolidineacetamide racetam nootropic with selective high-affinity choline uptake potentiation

    A lipophilic piracetam analog developed at Parke-Davis as a cognition-enhancing agent, distinguished from the parent racetam by potent modulation of hippocampal high-affinity choline uptake and marketed in select European jurisdictions for age-related cognitive impairment and attention deficits.

    Abstract

    Pramiracetam (CI-879; N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide; CAS 68497-62-1; molecular formula C14H27N3O2; molecular weight 269.39 g/mol) is a second-generation nootropic of the racetam class, synthesized at Parke-Davis in the late 1970s as a structural analog of piracetam. The compound differs from piracetam by replacement of the primary amide group with a diisopropylaminoethyl amide, a modification that substantially increases lipophilicity, central nervous system penetration, and effective potency, permitting therapeutic doses approximately five to ten times lower than equivalent piracetam regimens. Pramiracetam was advanced through preclinical and clinical development at Parke-Davis (then a division of Warner-Lambert, subsequently acquired by Pfizer) with the development code CI-879. The compound was licensed to Menarini for European development and was marketed under the trade names Pramistar, Neupramir, and Remen in Italy, Belgium, and several Eastern European jurisdictions for the treatment of memory and attention deficits in aging populations with neurodegenerative and vascular dementias. The Italian marketing authorization under Menarini was maintained until 2020, when it was voluntarily withdrawn by the manufacturer. The principal pharmacological mechanism of pramiracetam, characterized in the Pugsley et al. (1983) and subsequent studies, is selective enhancement of high-affinity choline uptake (HACU) in hippocampal and cortical cholinergic nerve terminals [1]. HACU is the rate-limiting step in acetylcholine biosynthesis; pramiracetam increases the velocity of choline transport into presynaptic cholinergic neurons without altering monoamine neurotransmitter concentrations, receptor binding profiles at dopaminergic, serotonergic, adrenergic, or histaminergic sites, or monoamine oxidase activity. The selectivity of the HACU mechanism distinguishes pramiracetam from piracetam, which acts predominantly through AMPA receptor positive allosteric modulation and membrane fluidity enhancement. Additional preclinical findings include increased nitric oxide synthase activity in rat cerebral cortex following systemic administration [2] and normalization of age-related electroencephalographic abnormalities in aged Fischer-344 rats [3]. The compound does not exhibit direct cholinesterase inhibition, muscarinic or nicotinic receptor agonism, or GABAergic activity at pharmacologically relevant concentrations. Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption, with peak plasma concentrations attained in approximately two to three hours; a plasma elimination half-life of 4.5 to 6.5 hours; linear dose-proportional exposure across the studied dose range (400 to 1600 mg); negligible plasma protein binding; and predominantly renal excretion of unchanged drug with minimal hepatic metabolism [4, 5]. The absence of significant cytochrome P450 involvement reduces drug-drug interaction liability relative to hepatically metabolized nootropic and cholinergic agents. The clinical evidence base includes a two-phase placebo-controlled trial in probable Alzheimer disease conducted at the National Institutes of Neurological Disorders and Stroke (Claus et al., 1991), which found that doses up to 4000 mg daily were unlikely to confer symptomatic benefit in moderate-to-severe Alzheimer disease [6]; a placebo-controlled study of scopolamine-induced amnesia in healthy volunteers demonstrating partial reversal of anticholinergic memory impairment in both young and elderly subjects [7]; a small open-label study in traumatic brain injury rehabilitation showing improved cognitive recovery [8]; and the European registration trials conducted by Menarini supporting the indication for memory and attention deficits in elderly patients with neurodegenerative and vascular dementias. Effect sizes across these studies are consistently small to moderate, and the compound has not produced a positive Phase 3 registration-quality readout in Alzheimer disease. Pramiracetam is not approved by the United States Food and Drug Administration and is classified as an unapproved new drug in the United States. It is available as a research-grade chemical from multiple suppliers. This monograph documents the chemistry, synthesis, and structural pharmacology of pramiracetam; the high-affinity choline uptake mechanism and supporting preclinical pharmacology; the comprehensive human pharmacokinetic record; the clinical evidence base across cognitive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications for research use; adverse-event signal; and a structured comparative assessment of five racetam-class and cholinergic nootropic compounds against pramiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1429Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Oxiracetam

    Plain-language summaryIntrigue 55 / 100

    Oxiracetam is a hydroxylated piracetam analog with reportedly stimulating cognitive effects. It is widely used in Italy and other European countries for cognitive impairment. Effects include enhanced memory consolidation in animal studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    2-Pyrrolidinone nootropic of the racetam family with positive allosteric modulation of AMPA-type glutamate receptors and protein kinase C activation

    A hydroxylated cyclic derivative of gamma-aminobutyric acid developed by ISF in Italy as a second-generation racetam nootropic, distinguished from piracetam by enhanced potency, positive allosteric modulation of AMPA receptors, stimulation of membrane-bound protein kinase C, and augmentation of hippocampal glutamate and acetylcholine release.

    Abstract

    Oxiracetam (ISF 2522, CGP 21690E) is a synthetic nootropic of the 2-pyrrolidinone (racetam) class, first synthesized in 1974 at the Istituto di Ricerche Farmacologiche (ISF) in Milan and introduced to the Italian market in 1984 under the trade name Neuromet for the treatment of cognitive disorders associated with primary degenerative dementia and multi-infarct dementia of mild to moderate degree. The compound is the 4-hydroxy analog of piracetam, the parent racetam; the hydroxyl substitution at position 4 of the pyrrolidinone ring produces a chiral center and confers approximately 2- to 5-fold greater potency than piracetam in standard rodent learning and memory paradigms and in in vitro assays of neurotransmitter release and synaptic potentiation. Oxiracetam is supplied and marketed as the racemic mixture of (R)- and (S)-enantiomers, though recent research has identified (S)-oxiracetam as the pharmacologically active enantiomer responsible for cognitive improvement in chronic cerebral hypoperfusion models.

    The mechanism of action of oxiracetam is multimodal and incompletely characterized at the molecular level, consistent with the broader racetam class. The principal identified activities include positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, producing enhanced glutamatergic neurotransmission and facilitation of long-term potentiation in hippocampal circuits; stimulation of membrane-bound protein kinase C (PKC), particularly the alpha and gamma isoforms, with consequent phosphorylation of substrates involved in memory consolidation and synaptic plasticity; augmentation of hippocampal acetylcholine release through modulation of cholinergic interneuron excitability; and stimulation of phospholipid metabolism in neuronal membranes. Oxiracetam also increases the release of endogenous glutamate and D-aspartic acid from depolarized hippocampal slices, supporting a presynaptic facilitatory component of its mechanism. A 2020 study further demonstrated that oxiracetam attenuates amyloid-beta-induced microglial activation and reduces neuroinflammatory cytokine release (interleukin-1-beta, interleukin-6, and tumor necrosis factor alpha), adding an anti-inflammatory dimension to the pharmacological profile.

    Pharmacokinetics in humans are characterized by oral bioavailability of 56 to 82 percent, peak plasma concentrations within 1 to 3 hours of dosing, and an elimination half-life of approximately 8 hours in healthy subjects. The compound is not appreciably metabolized; approximately 84 percent of an administered oral dose is recovered unchanged in urine within 24 hours, reflecting predominantly renal clearance. Brain penetration is modest, with central nervous system concentrations reaching approximately 5.3 percent of simultaneous blood levels. In patients with renal impairment, the elimination half-life extends to 10 to 68 hours, necessitating dose adjustment. The compound does not bind significantly to plasma proteins and does not undergo hepatic cytochrome P450 metabolism, resulting in a low drug-drug interaction potential.

    The clinical evidence base spans multiple indications. In mild to moderate dementia of the Alzheimer type and multi-infarct dementia, multicenter randomized placebo-controlled trials conducted in Italy in the late 1980s and early 1990s demonstrated statistically significant improvements in cognitive function at 800 mg twice daily for 12 to 52 weeks, measured by the Mini Mental State Examination, memory batteries, and functional scales. A negative trial in Alzheimer’s disease (Green et al., 1992) and mixed results in traumatic brain injury temper the clinical profile. More recently, a 2025 multicenter phase 3 trial of the purified (S)-enantiomer (L-oxiracetam) in 590 patients with mild to moderate traumatic brain injury reported significantly greater cognitive improvement than both racemic oxiracetam and placebo at 90 days. A 2023 phase IV trial of racemic oxiracetam in post-stroke vascular cognitive impairment in South Korea did not support efficacy in preventing cognitive decline. The compound is approved as a prescription medicine in Italy, select European countries, Argentina, and China; it is not approved by the United States Food and Drug Administration.

    This monograph reviews the chemistry, stereochemistry, and synthesis of oxiracetam; the multimodal molecular pharmacology including AMPA receptor modulation, PKC activation, neurotransmitter release augmentation, and anti-inflammatory activity; the comprehensive human pharmacokinetic record; the clinical evidence base across dementia, vascular cognitive impairment, traumatic brain injury, and neuroprotection indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five nootropic alternatives against oxiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1427Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Coluracetam

    Plain-language summaryIntrigue 50 / 100

    Coluracetam is a quinoline-fused racetam developed by BrainCells Inc. for major depressive disorder. It enhances high-affinity choline uptake. Phase 2 trials were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    2-Pyrrolidinone-based racetam nootropic and high-affinity choline uptake enhancer

    A synthetic racetam derivative developed at Mitsubishi Tanabe Pharma as a high-affinity choline uptake enhancer for Alzheimer’s disease, subsequently repositioned for major depressive disorder with comorbid generalized anxiety disorder, and distinguished from other racetams by a primary mechanism of action centered on choline transporter modulation rather than direct receptor agonism.

    Abstract

    Coluracetam (MKC-231, BCI-540) is a synthetic nootropic compound of the racetam structural class, characterized by a 2-oxopyrrolidinylacetamide pharmacophore fused to a tetrahydrofuroquinoline ring system, and distinguished from other racetam-class agents (piracetam, aniracetam, pramiracetam, oxiracetam) by a primary mechanism of action centered on the enhancement of high-affinity choline uptake (HACU), the rate-limiting step in acetylcholine biosynthesis. The compound was synthesized at the Mitsubishi Tanabe Pharma Corporation in the early 1990s as part of a medicinal chemistry program targeting cholinergic neurotransmission deficits in Alzheimer’s disease. Preclinical characterization in the ethylcholine aziridinium (AF64A) cholinotoxin rat model demonstrated that oral administration of MKC-231 at 0.3 to 10 mg/kg produced dose-dependent restoration of hippocampal high-affinity choline uptake activity, normalization of acetylcholine synthesis and release in hippocampal synaptosomes, and long-lasting cognitive improvement in Morris water maze and Y-maze paradigms that persisted beyond the elimination of the compound from plasma, suggesting a durable regulatory change in choline transporter (CHT1) expression or trafficking rather than a transient pharmacodynamic effect [1, 2, 3]. The Murai et al. (1994) study in ethylcholine aziridinium-treated mice provided the initial demonstration that MKC-231 ameliorated working memory deficits and restored hippocampal acetylcholine levels without producing the tremor, salivation, or hypothermia characteristic of direct cholinomimetic agents such as tacrine [4]. The compound advanced through Phase 2 clinical trials at Mitsubishi Tanabe for Alzheimer’s disease but failed to meet primary efficacy endpoints, and development for that indication was discontinued.

    In 2006, BrainCells, Inc. in-licensed coluracetam under the designation BCI-540 and repositioned it for major depressive disorder (MDD) with comorbid generalized anxiety disorder (GAD). A Phase 2a randomized, double-blind, placebo-controlled trial in 101 evaluable patients with treatment-resistant MDD (defined as failure of an average of two prior antidepressant trials) reported no statistically significant benefit of BCI-540 at 80 mg once daily or three times daily over placebo in the overall population at six weeks on either the Hamilton Rating Scale for Depression (HAM-D) or the Hamilton Rating Scale for Anxiety (HAM-A). However, a pre-specified subgroup analysis in patients with comorbid MDD and GAD demonstrated a 12.2-point improvement on the HAM-D in the three-times-daily dosing cohort compared to 5.5 points in the placebo group (p < 0.008), and a corresponding improvement in anxiety symptoms [5]. The compound was well tolerated in this trial, with a side-effect profile similar to placebo. BrainCells, Inc. subsequently ceased active operations, and no further clinical trials have been reported.

    Beyond the cholinergic mechanism, coluracetam has been characterized as a positive modulator of AMPA-type glutamate receptors (an “ampakine” property shared with aniracetam and some other racetams), though this activity is less well characterized than the HACU enhancement and the functional contribution to the in vivo pharmacology is uncertain [6]. The compound is not approved by any regulatory authority for any indication. It is supplied as a research-grade preparation by multiple chemical suppliers and is used in nootropic research contexts. Investigators should obtain analytical confirmation of identity and purity on every lot. This monograph reviews the chemistry, synthesis, and structural class of coluracetam; the HACU enhancement mechanism and supporting molecular pharmacology; the pharmacokinetic profile; the preclinical evidence base in cholinergic deficit models; the clinical evidence from the Phase 2a MDD/GAD trial; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five racetam and cholinergic nootropic alternatives against coluracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1432Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Centrophenoxine (Meclofenoxate)

    Plain-language summaryIntrigue 56 / 100

    Centrophenoxine is an ester of DMAE that crosses into the brain to support cognitive function and remove lipofuscin (cellular waste pigment). Used historically for age-related cognitive decline. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Cholinergic precursor ester combining dimethylaminoethanol and 4-chlorophenoxyacetic acid with lipofuscin-clearing and neuroprotective activity

    A synthetic ester of dimethylaminoethanol and para-chlorophenoxyacetic acid developed in 1959 at the French National Scientific Research Center, distinguished from other cholinergic precursors by its capacity to reduce neuronal lipofuscin accumulation and to enhance phospholipid membrane turnover in aging brain tissue.

    Abstract

    Centrophenoxine (meclofenoxate, Lucidril; 2-(dimethylamino)ethyl (4-chlorophenoxy)acetate; CAS 51-68-3; molecular formula C12H16ClNO3; molecular weight 257.71 g/mol) is a synthetic cholinergic precursor and neuroprotective agent developed in 1959 at the Centre National de la Recherche Scientifique (CNRS) in France. The compound is an ester of two biologically active moieties: dimethylaminoethanol (DMAE), a naturally occurring aminoalcohol found in small quantities in the human brain and implicated in choline and phospholipid metabolism, and para-chlorophenoxyacetic acid (pCPA), a synthetic auxin derivative that serves as a lipophilic carrier facilitating blood-brain barrier penetration and extending the biological half-life of the DMAE component. Following oral administration, centrophenoxine undergoes rapid hepatic ester hydrolysis to release DMAE and pCPA. The DMAE moiety is subsequently methylated to choline, which enters the acetylcholine synthetic pathway and is incorporated into membrane phospholipids as phosphatidyldimethylaminoethanol and phosphatidylcholine. The compound’s most distinctive pharmacological feature is the reduction of lipofuscin, the heterogeneous age pigment that accumulates progressively in postmitotic cells including cortical and hippocampal neurons, cardiac myocytes, and retinal pigment epithelium. The lipofuscin-clearing activity was first demonstrated by Nandy and Bourne in 1966 in senile guinea pig neurons and has been replicated across multiple rodent species, with reductions of 25 to 40 percent in cortical and hippocampal lipofuscin content following chronic oral administration at doses of 40 to 80 mg/kg/day for three to six months [1, 2]. The mechanism of lipofuscin clearance is incompletely characterized but is attributed to a combination of enhanced lysosomal enzyme activity, increased membrane phospholipid turnover (which dilutes the lipofuscin granule burden through membrane remodeling), and direct free radical scavenging by the DMAE moiety, which is incorporated into neuronal membranes as phosphatidyl-DMAE and functions as a hydroxyl radical scavenger [3, 4]. The clinical evidence base in human cognitive impairment spans approximately five decades but is modest in scale and quality by contemporary standards. The largest double-blind, randomized, placebo-controlled trial in healthy elderly subjects (Marcer and Hopkins, 1977; n = 50) demonstrated significant improvement in delayed free recall after three months of oral centrophenoxine at 600 mg twice daily, with no effect on immediate recall, digit span, or recognition memory, suggesting a selective enhancement of memory consolidation into long-term storage [5]. A second double-blind trial in 50 patients with organic dementia (Pek and Fulop, 1983) reported improvement in 48 percent of centrophenoxine-treated subjects versus 28 percent on placebo, although with high variability and methodological limitations [6]. Smaller open-label and controlled studies have reported improvements in vigilance, reaction time, and subjective mental alertness in elderly populations. The compound is marketed as a prescription medicine in several European countries (France, Germany, Hungary, Austria), in Japan, and in parts of Latin America for indications including senile cognitive impairment, post-stroke cognitive rehabilitation, and alcohol-related cognitive decline. It is not approved by the United States Food and Drug Administration and is sold as a research chemical in the United States. Pharmacokinetics are characterized by rapid oral absorption, rapid hepatic ester hydrolysis (plasma half-life of the parent ester is approximately 30 to 60 minutes), and a longer effective duration attributable to the persistence of the DMAE metabolite in brain tissue. Typical clinical doses range from 600 to 2000 mg per day in two or three divided administrations. The adverse-event profile is favorable; the most commonly reported effects are mild gastrointestinal discomfort, insomnia, and headache, generally at higher doses and resolving with dose reduction. This monograph reviews the chemistry, synthesis, and structural pharmacology of centrophenoxine; the lipofuscin-clearing, cholinergic, antioxidant, and membrane-modifying mechanisms; the pharmacokinetic profile; the preclinical and clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions with racetams and other cholinergic agents; the adverse-event and safety profile; and a comparative assessment of five cholinergic and neuroprotective alternatives (alpha-GPC, citicoline, DMAE, piracetam, and idebenone) against centrophenoxine on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1445Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.